Physician profile
Michael Ryan Wolfenbarger
NPI 1497474605
$4,137.91
in general payments reported to CMS, 2019-2025
18 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $683 · 2024: $1,653 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.07 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.45 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $593.53 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $409.68 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $404.79 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.63 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $251.25 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $244.66 | 2023-2025 | Trintellix |
| Alkermes, INC. | $217.52 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $201.51 | 2024-2025 | Austedo Xr, Uzedy |
| Almatica Pharma LLC | $194.81 | 2023-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $168.65 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $116.67 | 2023-2025 | Auvelity |
| Lundbeck LLC | $91.34 | 2023-2025 | Rexulti |
| Corium, LLC | $71.27 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $48.18 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $46.62 | 2024-2025 | Sublocade, Perseris |
| Bausch Health US, LLC | $37.59 | 2025 | Aplenzin |
| Sage Therapeutics, LLC | $14.76 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wolfenbarger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.